Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ZD-1839 (AstraZeneca).

¹Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)

|September 29, 2001

Summary

This summary is machine-generated.

AstraZeneca is developing ZD-1839, an epidermal growth factor receptor 1 (EGFR1) tyrosine kinase inhibitor, for treating cancers like non-small cell lung cancer. Phase III studies are underway, with potential FDA Fast Track status and projected launch in 2004-2006.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019

Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017

Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016

Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016

Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Oncology
Pharmacology

Background:

Epidermal growth factor receptor (EGFR) overexpression is implicated in various cancers, including non-small cell lung cancer (NSCLC) and pancreatic cancer.
ZD-1839 is an investigational drug developed by AstraZeneca targeting the tyrosine kinase activity of EGFR1.

Purpose of the Study:

To evaluate the efficacy and safety of ZD-1839 as a potential treatment for cancers overexpressing EGFR.
To assess the clinical development progress and market potential of ZD-1839.

Main Methods:

Phase III clinical studies initiated by August 2000.
Monitoring of regulatory submissions and expected timelines for market approval.
Analysis of financial analyst predictions regarding sales forecasts and market launch dates.

Related Experiment Videos

Main Results:

ZD-1839 received Fast Track designation from the US FDA.
First clinical results were anticipated at the 2001 AACR and ASCO meetings.
Financial analysts projected significant sales, with estimates ranging from millions to potentially $1 billion in peak sales.

Conclusions:

ZD-1839 shows promise as a targeted therapy for EGFR-overexpressing cancers.
The drug's development is progressing through late-stage clinical trials.
Market entry was projected between 2004 and 2006, with substantial commercial potential.